Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 2

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 capital      (5,011,891)  (5,011,891)Accumulated deficit      (5,391,110)  (3,442,620)Accumulated other comprehensive losses      (112,547)  (555,000)TOTAL STOCKHOLDERS’ EQUITY      6,816,262   8,322,804              TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY     $7,621,228  $10,433,848 

* Issued and outstanding shares of common stock have been adjusted as below:

for the periods prior to April 7, 2025, to reflect the 1-for-10 reverse stock split effected on that date on a retroactive basis as described in Note 12.

See accompanying notes to the consolidated financial statements.

 5Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS)  

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

 (Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Three months ended  Nine months ended   September 30,  September 30,   2025  2024  2025  2024              REVENUE (including $25,649 and $23,456 of revenue from related parties for the three months period ended September 30, 2025 and 2024 respectively, including $57,632 and $65,380 of revenue from related parties for the nine months period ended September 30, 2025 and 2024 respectively) $2,543,823  $2,630,376  $6,941,151  $6,986,791                  COST OF REVENUE (including $7,233 and $192,171 of cost of revenue from related parties for the three months period ended September 30, 2025 and 2024, respectively, including $9,404 and $293,770 of cost of revenue from related parties for the nine months period ended ended September 30, 2025 and 2024, respectively)  (2,166,138)